This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute myeloid leukemia targets for bispecific antibodies
Blood Cancer Journal Open Access 03 February 2017
-
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Journal of Hematology & Oncology Open Access 31 January 2017
-
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
Gene Therapy Open Access 11 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Loren AW, Porter DL . Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483–493.
Klingebiel T, Lang P, Schumm M, Koehl U, Bader P, Schwabe D et al. Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. Pathol Biol (Paris) 2005; 53: 159–161.
Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377–384.
Jeha S . New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 76–88.
Baeuerle PA, Kufer P, Bargou R . BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974–977.
Topp MS, Goekbuget N, Kufer P, Zugmaier G, Klinger M, Degenhard E et al. Blinatumomab (anti-CD19 bite) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): update of an ongoing phase II study. Haematologica 2009; 94 (Suppl 2): 195.
Lang P, Handgretinger R . Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 2008; 42 (Suppl 2): S54–S59.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Handgretinger, R., Zugmaier, G., Henze, G. et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25, 181–184 (2011). https://doi.org/10.1038/leu.2010.239
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.239
This article is cited by
-
Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia
Bone Marrow Transplantation (2019)
-
Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Current Oncology Reports (2019)
-
Prevention and treatment of relapse after stem cell transplantation with immunotherapy
Bone Marrow Transplantation (2018)
-
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Journal of Hematology & Oncology (2017)
-
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
Gene Therapy (2017)